Ipamorelin
Also known as: IPA, NNC 26-0161
Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin and stimulates the release of growth hormone from the pituitary gland. It is one of the cleanest GH-releasing peptides with minimal effect on cortisol and prolactin levels.
Research Status
Research compound - not FDA approved
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Mild redness, swelling, or bruising at the injection site. Typically resolves within 24 hours. Minimise by rotating sites, allowing peptide to warm to room temperature, and using proper injection technique. Apply ice if swelling persists.
Transient headache may occur within 1-2 hours of injection, likely related to rapid GH elevation. Usually self-resolving. Ensure adequate hydration and consider timing injection earlier in the evening if nocturnal headache occurs.
Transient flushing or sensation of warmth may occur 15-30 minutes post-injection due to GH-mediated vasodilation. Self-resolving within 30-60 minutes.
Ghrelin receptor activation may transiently increase appetite, particularly if injected in the morning or early evening. This typically diminishes with continued use as the body adapts.
GH is counter-regulatory to insulin; individuals with insulin resistance, prediabetes, or diabetes may experience elevated fasting glucose or HbA1c. Monitor blood glucose regularly, especially if diabetic. Discontinue if significant hyperglycaemia develops and consult a healthcare provider.
Prolonged GH elevation can cause fluid retention and nerve compression, leading to CTS symptoms (numbness, tingling in hands). More likely with high doses or prolonged use. If symptoms develop, reduce dose, increase rest periods, or discontinue. Consult a healthcare provider if symptoms persist.
Transient myalgia or arthralgias may occur as GH stimulates protein synthesis and tissue remodelling. Usually mild and self-resolving. Ensure adequate protein intake and hydration.
Repeated injections in the same site can cause localised lipoatrophy (fat loss) or lipohypertrophy (fat thickening). Prevent by strictly rotating injection sites with each dose. If lipodystrophy develops, discontinue injections in that area for 4-6 weeks.
Mild nausea may occur within 1-2 hours of injection, particularly if injected on a full stomach. Typically self-resolving. Inject on an empty stomach or fasted state to minimise.
Transient dizziness may occur due to rapid GH elevation and metabolic changes. Ensure adequate hydration and avoid standing abruptly after injection. Sit or lie down if symptoms occur.
Anaphylaxis or severe allergic reaction is extremely rare but possible. Symptoms include difficulty breathing, throat swelling, severe rash, or hypotension. Seek emergency medical care immediately if suspected. Discontinue use and inform healthcare provider of the reaction.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 200-300 mcg |
| Frequency | 1-3x daily |
| Timing | Before bed, post-workout, or upon waking (fasted) |
| Route | Subcutaneous |
Can be stacked with CJC-1295 for synergistic effects.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 711.9 g/mol |
| Half-life | 2 hours (plasma); GH response peaks 30-60 minutes post-injection |
| Sequence | His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 |
Ipamorelin is a selective growth hormone secretagogue that acts as a ghrelin receptor agonist (GHS-R1a), stimulating the pituitary gland to release endogenous growth hormone. Unlike some other GH secretagogues, ipamorelin demonstrates high selectivity for GH release with minimal stimulation of cortisol or prolactin, making it one of the cleanest GH-releasing peptides available. It works synergistically with GHRH (growth hormone-releasing hormone) to amplify the natural pulsatile GH secretion pattern.
Ghrelin Receptor (GHS-R1a) Activation
Ipamorelin binds to ghrelin receptors on somatotroph cells in the anterior pituitary, triggering depolarisation and calcium influx, which stimulates GH granule exocytosis and release into circulation.
GHRH Synergy
Ipamorelin enhances the effect of endogenous GHRH, amplifying GH pulse amplitude and frequency without suppressing somatostatin (the natural GH inhibitor), resulting in more physiological GH secretion patterns.
Minimal Neuroendocrine Off-Target Effects
Unlike some GH secretagogues, ipamorelin shows minimal binding to prolactin or ACTH receptors, resulting in negligible cortisol and prolactin elevation — a key advantage for long-term use.
- Ipamorelin is a hexapeptide (6 amino acids) with high selectivity for GH secretion and minimal off-target endocrine effects
- It stimulates GH release in a pulsatile, physiological manner rather than causing sustained elevation, reducing tachyphylaxis risk
- Cortisol and prolactin remain largely unaffected at therapeutic doses, distinguishing it from older GH secretagogues
- Efficacy is enhanced when combined with GHRH analogues (e.g., CJC-1295 or sermorelin) due to synergistic pathway activation
- GH response is sleep-dependent and fasting-dependent; timing of injection (pre-sleep or fasted morning) optimises release
Track your Ipamorelin research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Ipamorelin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.